Impact of Pharmacogenetic Markers on the Safety of Macrolide Therapy in Patients with Bacterial Complications of Influenza

Skryabina A. A.
Assistant, Chair for Infectious Diseases and Epidemiology, Faculty of Medicine¹

Nikiforov V. V.
Doctor of Medicine, Head, Chair for Infectious Diseases and Epidemiology, Faculty of Medicine¹

Shakhmardanov M. Z.
Doctor of Medicine, Professor, Chair for Infectious Diseases and Epidemiology, Faculty of Medicine¹

Leontieva O. V.
Infectious Disease Doctor²

Kostritskaya S. S.
Infectious Disease Doctor²

Schetinina T. S.
Infectious Disease Doctor²

Sychev D. A.
Academician of the Russian Academy of Sciences, Doctor of Medicine, Professor, Head, Chair for Clinical Pharmacology and Therapy³

1 - Pirogov Russian National Research Medical University, Moscow, Russia
2 - Infectious Clinical Hospital No.1, Moscow, Russia
3 - Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Skryabina Anna Aleksandrovna; e-mail: anna.skryabina.85@mail.ru

The study had no sponsorship.

None declared.

Background. Macrolides are a class of broad-spectrum antibiotics used to treat a variety of infectious diseases, both local and systemic. Although the use of macrolides is generally considered safe, some patients may be at risk of dose-dependent adverse drug reactions (ADRs), which may reduce the safety of treatment for this category of patients. Purpose of the study. To investigate the influence of polymorphism of genes encoding transporter proteins and biotransformation enzymes of macrolide antibiotics on the safety of therapy in patients with bacterial complications of influenza. Material and methods. An open non-comparative prospective study was conducted in which 100 patients diagnosed with bacterial complications of influenza from the lower respiratory tract (ICD-10 diagnosis codes J10.0-J10.1), treated in an infectious disease hospital, received macrolide antibiotics (azithromycin or erythromycin) in tablet form for 5 days. Genotyping was performed by real-time polymerase chain reaction with allele-specific hybridization. Results. The presence of statistically significant influence of the 3435C>T (rs1045642) polymorphic marker of the ABCB1 gene on the frequency of ADRs development in patients treated with macrolides was found: estimation – 0.751, OR = 2.12 (95% CI: 1.03 – 4.34), p = 0.043. In addition, the presence of a statistically significant effect of polymorphic marker C>T intron 6 (rs35599367) of the CYP3A4 gene on the overall incidence of ADRs in patients treated with erythromycin was revealed: estimation – 3.1781, OR = 24.0 (95% CI: 1.2775 – 450.9741), p = 0.0339; and on the incidence of abdominal pain and abdominal discomfort: estimation – 2.0794, OR = 8 (95% CI: 1.0377 – 61.7143), p = 0.046. Discussion: in patients carrying the CT and TT genotypes of the 3435C>T (rs1045642) polymorphic marker of the ABCB1 gene, a higher frequency of such ADRs as abdominal pain and discomfort in the abdomen and diarrhea was observed. Furthermore, the statistically significant influence of the C>T intron 6 (rs35599367) polymorphic marker of the CYP3A4 gene on the frequency of ADRs development against the background of erythromycin use was shown. Conclusion: the influence of ABCB1 genetic polymorphism on the safety parameters of macrolide therapy was demonstrated. It was found that carriage of the C>T intron 6 (rs35599367) polymorphic marker of the CYP3A4 gene may allow to predict the development of ADRs (and specifically abdominal pain) against the background of erythromycin use.

pharmacogenetics, adverse reactions, macrolides, biotransformation, personalized medicine

10.29234/2308-9113-2024-12-3-141-154

1. Lazareva N.B., Rebrova E.V., Rjazanova A.Ju., Bondarenko D.A., Savinceva D.D. Makrolidy: sovremennaja pozicija v pul'monologicheskoj praktike. [Macrolides: current position in pulmonologic practice.] Prakticheskaja pul'monologija [Practical Pulmonology] 2019; (1): 66-77. (In Russ.)

2. Hansen M.P., Scott A.M., McCullough A., Thorning S., Aronson J.K., et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev 2019 Jan 18; 1(1): CD011825, doi: 10.1002/14651858.CD011825.pub2

3. Skrjabina A.A., Tereshkin N.A., Nikiforov V.V., Kashirin V.I., Antipjat N.A., Zastrozhin M.S., Sychev D.A. Primenenie metoda global'nyh triggerov dlja vyjavlenija nezhelatel'nyh lekarstvennyh reakcij u pacientov stacionara infekcionnogo profilja. [Application of the global triggers tool to identify adverse drug reactions in infectious disease inpatients.] Medicina [Medicine] 2023; 11(2): 42-55, doi: 10.29234/2308-9113-2023-11-2-42-55 (In Russ.)

4. Chebotarev V.V., Ashakov M.S., Chebotareva N.V., Shhetinin E.V. Makrolidy v lechenii urogenital'noj infekcii: dokazannaja jeffektivnost' ili marketingovaja politika farmacevticheskih kompanij? [Macrolides in the treatment of urogenital infections: proven efficacy or marketing policy of pharmaceutical companies?] Medicina [Medicine] 2018; 6(1): 25-41, doi: 10.29234/2308-9113-2018-6-1-25-41 (In Russ.)

5. Fohner A.E., Sparreboom A., Altman R.B., Klein T.E. PharmGKB summary: macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics 2017; 27(4): 164-167, doi: 10.1097/FPC.0000000000000270

6. Skrjabina A.A., Nikiforov V.V., Shahmardanov M.Z., Zastrozhin M.S., Sychev D.A. Osobennosti farmakokinetiki i farmakogenetiki antibiotikov iz gruppy makrolidov (obzor literatury). [Peculiarities of pharmacokinetics and pharmacogenetics of antibiotics from the group of macrolides (literature review).] Immunopatologija, allergologija, infektologija [Immunopathology, Allergology, Infectology] 2022; (1): 11-16. (In Russ.)

7. Smirnov A.P., Shamkina P.A., Krivopalov A.A., Janov Ju.K., Shnajder N.A., et al. Personalizirovannyj podhod k primeneniju makrolidov v lechenii oslozhnennyh form ostryh bakterial'nyh rinosinusitov. [Personalized approach to the use of macrolides in the treatment of complicated forms of acute bacterial rhinosinusitis.] Folia Otorhinolaryngologiae et Pathologiae Respiratoriae 2019; 25(3): 60-72. (In Russ.)

8. Lynch T., Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007; 76(3): 391-396.

9. Bel'diev S.N., Egorova I.V., Kononova A.G., Medvedeva I.V., Platonov D.Ju., Kolbasnikov S.V. Mify o lekarstvennyh vzaimodejstvijah Dzhozamicina. [Myths about drug interactions of Josamycin.] Medicina [Medicine] 2020; 8(2): 10-30, doi: 10.29234/2308-9113-2020-8-2-10-30 (In Russ.)

10. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug;30(2):239-245, doi: 10.1038/clpt.1981.154